Natural Products as Outstanding Alternatives in Diabetes Mellitus: A Patent Review.
Ingrid Andrea RodríguezMairim SerafiniIzabel Almeida AlvesKaren Luise LangFátima Regina Mena Barreto SilvaDiana Marcela AragónPublished in: Pharmaceutics (2022)
Diabetes mellitus (DM) is a metabolic syndrome that can be considered a growing health problem in the world. High blood glucose levels are one of the most notable clinical signs. Currently, new therapeutic alternatives have been tackled from clinicians' and scientists' points of view. Natural products are considered a promising source, due to the huge diversity of metabolites with pharmaceutical applications. Therefore, this review aimed to uncover the latest advances in this field as a potential alternative to the current therapeutic strategies for the treatment of DM. This purpose is achieved after a patent review, using the Espacenet database of the European Patent Office (EPO) (2016-2022). Final screening allowed us to investigate 19 patents, their components, and several technology strategies in DM. Plants, seaweeds, fungi, and minerals were used as raw materials in the patents. Additionally, metabolites such as tannins, organic acids, polyphenols, terpenes, and flavonoids were found to be related to the potential activity in DM. Moreover, the cellular transportation of active ingredients and solid forms with special drug delivery profiles is also considered a pharmaceutical technology strategy that can improve their safety and efficacy. From this perspective, natural products can be a promissory source to obtain new drugs for DM therapy.
Keyphrases
- glycemic control
- blood glucose
- metabolic syndrome
- drug delivery
- type diabetes
- ms ms
- public health
- healthcare
- insulin resistance
- mental health
- human health
- stem cells
- emergency department
- adipose tissue
- health information
- mesenchymal stem cells
- cancer therapy
- uric acid
- drug release
- combination therapy
- drug induced
- water soluble